Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Feb 27, 2025
Total revenue of $59.3 million for the fiscal year ended December 31, 2024
Expect double digit growth for total revenue in 2025
2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material; expect to secure GMP scale-up partner
Read more at globenewswire.comNASDAQ:CDXS (10/23/2025, 1:28:57 PM)
2.62
+0.06 (+2.34%)
Find more stocks in the Stock Screener
